A provisional consensus definition of cure in multiple myeloma has been established by the International Myeloma Society and the International Myeloma Working Group, shifting clinical focus from disease control to long-term remission benchmarks. Hans Lee, MD, director of myeloma research at the Sarah Cannon Research Institute, discussed the framework at the International Myeloma Society Annual Meeting in Glasgow, Scotland, noting that unprecedented depth of response in clinical trials prompted the update.
Consensus Criteria for Multiple Myeloma Cure
Historically regarded as a treatable but incurable hematologic malignancy, multiple myeloma is now being re-evaluated following modern clinical trial readouts. The newly developed international framework establishes three strict thresholds that a patient must meet to satisfy the provisional definition of a cure.
According to the consensus guidelines outlined by Hans Lee, MD, the criteria require:
- A minimum of 5 years off all antimyeloma therapy.
- At least 4 serial measurable residual disease (MRD) assessments confirming negativity throughout that 5-year interval.
- Negative functional imaging at both the start and the end of the specified time period.
Did you know? Data from the 5-year follow-up of the original phase 1b/2 CARTITUDE-1 study showed that roughly a third of treated patients remain alive with no evidence of relapse following ciltacabtagene autoleucel therapy.
Implications for Fixed-Duration Versus Continuous Therapy
Because the framework hinges on a multi-year treatment-free interval, Hans Lee, MD, stated that the criteria strengthen the rationale for fixed-duration regimens over continuous therapy administered until disease progression.
While the current criteria serve as an initial benchmark, researchers expect the definitions to evolve as more long-term survival and imaging data mature. “I think in myeloma, the time is now to really be thinking about cure, not just about control,” Hans Lee, MD, noted during his interview with Targeted Oncology at the Glasgow meeting.
Pro Tip: Clinicians tracking emerging hematology updates can review the full International Myeloma Society and International Myeloma Working Group announcement through prior coverage detailing global expert consensus criteria for cure in multiple myeloma.
Frequently Asked Questions
What defines a cure under the new multiple myeloma consensus?
The provisional criteria require patients to remain off all antimyeloma therapy for at least 5 years, confirm MRD negativity across at least 4 serial assessments during that time, and maintain negative functional imaging at the beginning and end of the interval.
Which therapies drove the development of this cure definition?
Unprecedented depth and durability of response, particularly with CAR T-cell therapies such as ciltacabtagene autoleucel, drove international experts to re-evaluate traditional myeloma outcomes.
Does this consensus replace continuous treatment models?
According to clinical researchers, the new definition strengthens the scientific rationale for fixed-duration treatment strategies rather than continuous therapy that runs until disease progression.
Join the Discussion: What are your thoughts on shifting clinical milestones from disease control to long-term cure criteria in hematology? Leave a comment below or explore our archives for more oncology updates and expert interviews.